Strategy for growth

Every day, we strive to build a broader and stronger Orexo. By doing so, we can improve many more lives, foster a more dynamic work environment, and generate value for our shareholders. Our efforts to strengthen and expand Orexo are built on three pillars.

Further details on the company’s strategic direction following the divestment of Zubsolv® US on 31 December 2025 will be presented at the company’s R&D Day in Q1 2026. Additional information will follow.

Build on a strong tradition in pharmaceutical development based on proprietary drug delivery technologies 

  • Maintain and strengthen the position of AmorphOX® technology as the world leader in nasal delivery of powder-based medicines
  • Expand into the field of biomolecules, such as GLP-1 agonists and vaccines.

Leverage financial capacity to support a continuous flow of proprietary projects developed to reach value-inflection points

  • OX640, for anaphylaxis, targeting a global market valued at over USD 2.3 billion,1 will be developed to approval
  • Izipry™, for the treatment of opioid overdoses, will be developed to approval
  • OX390, for overdoses caused by polysubstance abuse, will be developed at least to clinical proof of concept in collaboration with BARDA.2

1 https://www.fortunebusinessinsights.com/epinephrine-market-104291

2 Biomedical Advanced Research and Development Authority

AmorphOX can create new and improved opportunities for APIs in drug delivery and bioavailability. The technology also has the ability to stabilize sensitive substances and ensure better dose uniformity.

  • 21 APIs, both large and small molecules, have been successfully formulated into powder and demonstrated positive results for stabilizing the active substance.